Korean Circulation Journal

  • 제52권7호
  • /
  • Pages.556-557
  • /
  • 2022
  • /
  • 1738-5520(pISSN)
  • /
  • 1738-5555(eISSN)
대한심장학회 (The Korean Society of Cardiology)
권호 표지
DOI QR코드

DOI QR Code

Role of β-Blockers in Chronic Coronary Artery Disease Management in the Percutaneous Coronary Intervention Era: Good Symptom Control or Something More?

  • Ji Woong Roh (Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital) ;
  • Yongcheol Kim (Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital)
  • 투고 : 2022.04.13
  • 심사 : 2022.04.26
  • 발행 : 2022.07.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8. https://doi.org/10.1056/NEJM200105313442201
  2. Puymirat E, Riant E, Aissaoui N, et al. β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ 2016;354:i4801.
  3. Greenberg B. Medical management of patients with heart failure and reduced ejection fraction. Korean Circ J 2022;52:173-97. https://doi.org/10.4070/kcj.2021.0401
  4. Won H, Suh Y, Kim GS, Ko YG, Hong MK. Clinical impact of beta blockers in patients with myocardial infarction from the Korean National Health Insurance database. Korean Circ J 2020;50:499-508. https://doi.org/10.4070/kcj.2019.0231
  5. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407-77. https://doi.org/10.1093/eurheartj/ehz425
  6. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:87-165. https://doi.org/10.1093/eurheartj/ehy394
  7. Ozasa N, Morimoto T, Bao B, et al. β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure. Int J Cardiol 2013;168:774-9. https://doi.org/10.1016/j.ijcard.2012.10.001
  8. Motivala AA, Parikh V, Roe M, et al. Predictors, trends, and outcomes (among older patients ≥65 years of age) associated with beta-blocker use in patients with stable angina undergoing elective percutaneous coronary intervention: insights from the NCDR registry. JACC Cardiovasc Interv 2016;9:1639-48. https://doi.org/10.1016/j.jcin.2016.05.048
  9. Park J, Han JK, Kang J, et al. The clinical impact of β-blocker therapy on patients with chronic coronary artery disease after percutaneous coronary intervention. Korean Circ J 2022;52:544-55. https://doi.org/10.4070/kcj.2021.0395
  10. Ferrari R, Camici PG, Crea F, et al. Expert consensus document: a 'diamond' approach to personalized treatment of angina. Nat Rev Cardiol 2018;15:120-32. https://doi.org/10.1038/nrcardio.2017.131